A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors

Clinical Cancer Research

Volumn 5, Issue 11, 1999, Pages 3394-3402

  Glantz, Michael J ^a,b   Jaeckle, Kurt A ^c   Chamberlain, Marc C ^d   Phuphanich, Surasak ^e   Recht, Lawrence ^f   Swinnen, Lode J ^g   Maria, Bernard ^h   LaFollette, Susan ⁱ   Schumann, G Berry ^j   Cole, Bernard F ^k   Howell, Stephen B ^d  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UCSD MEDICAL CENTER   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g LOYOLA UNIVERSITY CHICAGO   (United States)

^h UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

ⁱ RUSH CANCER INSTITUTE   (United States)

^j Dianon Systems   (United States)

^k DARTMOUTH MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DEXAMETHASONE; FOLINIC ACID; METHOTREXATE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG SAFETY; FEMALE; HUMAN; INTRATHECAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MULTICENTER STUDY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CYTARABINE; DELAYED-ACTION PREPARATIONS; DISEASE PROGRESSION; FEMALE; HUMANS; INJECTIONS, SPINAL; LUNG NEOPLASMS; MALE; MELANOMA; MENINGEAL NEOPLASMS; METHOTREXATE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL RATE; SURVIVORS;

EID: 0032711629     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Bleyer, W. A. Leptomeningeal cancer in leukemia and solid tumors. Curr. Probl. Cancer, 12: 184-238, 1988.
2. Posner, J. B., and Chernik, N. L. Intracranial metastases from systemic cancer. Adv. Neurol., 19: 575-587, 1978.
3. Gonzalez-Vitale, J. C., and Garcia-Bunuel, R. Meningeal carcinomatosis. Cancer (Phila.), 37: 2906-2911, 1976.
4. Freilich, R. J., Seidman, A. D., and DeAngelis, L. M. Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer (Phila.), 76: 232-236, 1995.
5. Hitchins, R. N., Bell, D. R., Woods, R. L., and Levi, J. A. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J. Clin. Oncol., 5: 1655-1662, 1987.
6. Rosen, S. T., Aisner, J., Makuch, R. W., Matthews, M. J., Ihde, D. C., Whitacre, M., Glatstein, E. J., Wiernik, P. H., Lichter, A. S., and Bunn, P. A. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience. Medicine (Baltimore), 61: 45-63, 1982.
7. Nugent, J. L., Bunn, P. A., Matthews, M. J., Ihde, D. C., Cohen, M. H., Gazdar, A, and Minna, J. D. CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing patterns with lengthening survival. Cancer (Phila.), 44: 1885-1893, 1979.
8. Yap, H. Y., Yap, B. S., Tashima, C. K., Distefano, A., and Blumenschein, G. R. Meningeal carcinomatosis in breast cancer. Cancer (Phila.), 42: 283-286, 1978.
9. Shapiro, W. R., Posner, J. B., Ushio, Y., Chernik, N. L., and Young, D. F. Treatment of meningeal neoplasms. Cancer Treat. Rep., 61: 733-743, 1977.
10. Glass, J. P., Melamed, M., Chernik, N. L., and Posner, J. B. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology, 29: 1369-1375, 1979.
11. Wasserstrom, W. R., Glass, J. P., and Posner, J. B. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer (Phila.), 49: 759-772, 1982.
12. Bleyer, W. A., and Poplack, D. G. Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med. Pediatr. Oncol., 6: 207-213, 1979.
13. Glantz, M. J., Hall, W. H., Cole, B. F., Chozick, B. S., Shannon, C. M., Wahlberg, L., Akerley, W. A., Marin, L., and Choy, H. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer (Phila.), 75: 2919-2931, 1995.
14. 111indium-DTPA CSF flow studies. Neurology, 41: 1765-1769, 1991.
15. 111indium-DTPA ventriculography. Am. J. Med., 73: 641-647, 1982.
16. Kim, S., Khatibi, S., Howell, S. B., McCully, C., Balis, F. M., and Poplack, D. G. Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. Cancer Res., 53: 1596-1598, 1993.
17. Balis, F., and Poplack, D. Central nervous system pharmacology of antileukemic drugs. Am. J. Pediatr. Hematol. Oncol., 11: 74-86, 1989.
18. Strother, D. R., Glynn-Barnhart, A., and Kovner, E. Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing. J. Clin. Oncol., 7: 1741-1747, 1989.
19. Zimm, S., Collins, J. M., Miser, J., Chatterji, D., and Poplack, D. G. 1-β-D-Arabinofuranosylcytosine cerebrospinal fluid kinetics. Clin. Pharmacol. Ther., 35: 826-830, 1984.
20. Slevin, M., Piall, E. M., Aherne, G. W., Harvey, V. J., Johnston, A., and Lister, T. Effect of dose and schedule on pharmacokinetics of high-dose 1-β-D-arabinofuranosylcytosine in plasma and cerebrospinal fluid. J. Clin. Oncol., 1: 546-551, 1983.
21. Shapiro, W. R., Young, D. F., and Mehta, B. M. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N. Engl. J. Med., 293: 161-166, 1975.
22. Posner, J. B. Side effects of chemotherapy. In: J. B. Posner (ed.), Neurologic Complications of Cancer, pp. 282-310. Philadelphia: F. A. Davis Company, 1995.
23. Strong, J. M., Colling, M. M., Lester, C., and Poplack, D. G. Pharmacokinetics of intraventricular and intravenous N,N′,N″-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res., 46: 6101-6104, 1986.
24. Chamberlain, M. C. New approaches to and current treatments of leptomeningeal metastases. Curr. Opin. Neurol., 7: 492-500, 1994.
25. Bleyer, W. A., Poplack, D. G., and Simon, R. M. "Concentration × time" methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood, 51: 835-842, 1978.
26. Kim, S., Kim, D. J., Geyer, M. A., and Howell, S. B. Multivesicular liposomes containing 1-β-D-arabinofuranosylcytosine for slow-release intrathecal therapy. Cancer Res., 47: 3935-3937, 1987.
27. Chamberlain, M. C., Kormanik, P., Howell, S. B., and Kim, S. Pharmacokinetics of intralumbar DTC 101 for the treatment of leptomeningeal metastases. Arch. Neurol., 52: 912-917, 1995.
28. Kim, S., Chatelut, C., Kim, J. C., Howell, S. B., Cates, C., Kormanik, P. A., and Chamberlain, M. C. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J. Clin. Oncol., 11: 2186-2193, 1993.
29. Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., and Donomi, A. The functional assessment of cancer therapy scale: development and validation of the general measure. J. Clin. Oncol., 11: 570-579, 1993.
30. Balm, M., and Hammack, J. Leptomeningeal carcinomatosis: presenting features and prognostic factors. Arch. Neurol., 53: 626-632, 1996.
31. Fizazi, K., Asselain, B., Vincent-Salomon, A., Jouve, M., Dieras, V., Palangie, T., Beuzeboc, P., Dorval, T., and Pouillart, P. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer (Phila.), 77: 1315-1323, 1996.
32. Jayson, G. E., Howell, A., Harris, M., Morgenstern, G., Chang, J., and Ryder, W. D. Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer (Phila.), 74: 3135-3141, 1994.
33. Grossman, S. A., Finkelstein, D. M., Ruckdeschel, J. C., Trump, D. L., Moynihan, T., and Ettinger, D. S. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J. Clin. Oncol., 11: 561-569, 1993.
34. Boogerd, W., Hart, A. A. M., van der Sande, J. J., and Engelsman, E. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer (Phila.), 67: 1685-1695, 1991.
35. Chamberlain, M. C., and Kormanik, P. A. Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch. Neurol., 54: 1364-1368, 1997.
36. Grant, R., Naylor, B., Greenberg, H. S., and Junck, L. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch. Neurol., 57: 457-461, 1994.
37. Bokstein, F., Lossos, A., and Siegal, T. Leptomeningeal metastases from solid tumors. A comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer (Phila.), 82: 1756-1763, 1998.
38. 2: a preliminary report. J. Neuro-Oncol., 24: 109-122, 1995.
39. Berg, S. L., Balis, F. M., Zimm, S., Murphy, R. F., Holcenberg, J., Sato, J., Reaman, G., Steinhertz, P., Gillespie, A., and Doherty, K. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J. Clin. Oncol., 10: 143-148. 1992.
40. Adamson, P., Balis, F. M., Arndt, C. A., Holcenberg, J. S., Narang, P. K., Murphy, R. F., Gillespie, A. J., and Poplack, D. G. Intrathecal 6-mercaptopurine: preclinical pharmacology, Phase I/II trial, and pharmacokinetic study. Cancer Res., 57: 6079-6083, 1991.
41. Phillips, P. C. Methotrexate toxicity. In: D. A. Rottenberg (ed.), Neurological Complications of Cancer Treatment, pp. 115-134. Boston: Butterworth-Heineman, 1991.
42. Geiser, C. F., Bishop, Y., Jaffe, N., Furman, L., Traggis, D., and Frei, E., III. Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood, 45: 189-195, 1975.
43. Resar, L. M., Phillips, P. C., Kastan, M. B., Leventhal, B. G., Bowman, P. W., and Civin, C. I. Acute neurotoxicity after intrathecal 1-β-D-arabinofuranosylcytosine in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer (Phila.), 71: 117-123, 1993.
44. Baker, W. J., Royer, G. L., and Weiss, R. B. Cytarabine and neurological toxicity. J. Clin. Oncol., 4: 679-693, 1991.
45. Boogerd, W., Moffie, D., and Smets, L. A. Early blindness and coma during intrathecal chemotherapy for meningeal carcinomatosis. Cancer (Phila.), 65: 452-457, 1990.
46. Glantz, M. J. Diagnosis of radiation-induced nervous system injury. In: E. Feldmann (ed.), Current Diagnosis in Neurology, pp. 146-154. Philadelphia: Mosby-Year Book, Inc., 1994.
47. Fishman, M. L., Bean, S. C., and Cogan, D. G. Optic atrophy following prophylactic chemotherapy and cranial radiation for acute lymphocytic leukemia. Am. J. Ophthalmol., 82: 571-576, 1976.
48. Merriman, R. L., Hertel, L. W., Schultz, R. M., Houghton, P. J., Houghton, J. A., Rutherford, P. G., Tanzer, L. R., Boder, G. B., and Grindey, G. B. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest. New Drugs, 14: 243-247, 1996.
49. Kern, D. H., Morgan, C. R., and Hildebrand-Zanki, S. U. In vitro pharmacodynamics of 1-β-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). Cancer Res., 48: 117-121, 1988.
50. Kufe, D. W., Griffin, J. D., and Spriggs, D. R. Cellular and clinical pharmacology of low-dose ara-C. Semin. Oncol., 12: 200-207, 1985.
51. Davis, H. L., Jr., Rochlin, D. B., Weiss, A. J., Wilson, W. L., Andrews, N. C., Madden, R., and Sedransk, N. 1-β-D-Arabinofuranosylcytosine (NSC 63878) toxicity and antitumor activity in human solid tumors. Oncology (Basel), 29: 190-200, 1974.
52. Frei, E., III, Buckers, J. N., Hewlett, J. S., Lane, M., Leary, W. V., and Talley, R. W. Dose schedule and antitumor studies of 1-β-D-arabinofuranoxylcytosine (NSC 63878). Cancer Res., 29: 1325-1332, 1969.
53. Freilich, R. J., Krol, G., and DeAngelis, L. M. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann. Neurol., 38: 51-57, 1995.
54. Chamberlain, M. C., Sandy, A. D., and Press, G. A. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology, 40: 435-438, 1990.
55. Pfeffer, M. R., Wygoda, M., and Siegal, T. Leptomeningeal metastases: treatment results in 98 consecutive patients. Isr. J. Med. Sci., 24: 611-618, 1988.
56. Sause, W. T., Crowley, J., Eyre, H., Rivkin, S., Pukgh, R. P., Quagliana, J. M., Taylor, S. A., and Molnar, B. Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases: a Southwest Oncology Group study. J. Neuro-oncol., 6: 107-112, 1988.
57. Giannone, L., Greco, F. A., and Hainsworth, J. D. Combination intraventricular chemotherapy for meningeal neoplasia. J. Clin. Oncol., 4: 68-73, 1986.
58. Trump, D. L., Grossman, S. A., Thompson, G., Murray, K., and Wharam, M. Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate. Cancer Treat. Rep., 66: 1549-1551, 1982.
59. Glantz, M. J., Cole, B. F., Glantz, L. K., Cobb, J., Mills, P., Lekos, A., Walters, B. C., and Recht, L. D. Cerebrospinal fluid cytology in patients with cancer. Minimizing false-negative results. Cancer (Phila.), 82: 733-739, 1998.
60. Rogers, L. R., Duchesneau, P. M., Nunez, C., Fishleder, A. J., Weick, J. K., Bauer, L. J., and Boyett, J. M. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurology, 42: 1239-1241, 1992.
61. Murray, J. J., Greco, F. A., Wolff, S. N., and Hainsworth, J. D. Neoplastic meningitis. Marked variations of cerebrospinal fluid composition in the absence of extradural block. Am. J. Med., 75: 289-294, 1983.
62. 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology, 46: 1674-1677, 1996.
63. Larson, S. M., Schall, G. L., and Di Chiro, G. The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography. J. Nucl. Med., 12: 555-557, 1971.
64. Rieselbach, R. E., Di Chiro, G., Freilich, E. J., and Rall, D. P. Subarachnoid distribution of drugs after lumbar injection. N. Engl. J. Med., 267: 1273-1278, 1962.